The story has been updated to clarify that customers ending their subscription to Personal Genome Service will continue to have access to their raw genetic data.

By Tony Fong

NEW YORK (GenomeWeb News) – About one year after switching to a subscription-based model, consumer genetics testing firm 23andMe will limit access of subscribers who choose to end their subscriptions to their genetic data, a policy about-face that has left many subscribers up in arms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.